Rheumatoid Arthritis
Conditions
Keywords
Rheumatoid Arthritis
Brief summary
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose study designed to assess the safety, tolerability, pharmacokinetics, and immunogenicity of different dose levels of ABBV-257 given with methotrexate. ABBV-257 or placebo will be administered once every other week (EOW) for a total of 4 doses. Subjects will continue on their stable dose of methotrexate weekly throughout participation in the study. This study will be conducted in approximately 24 subjects in 3 dose groups, with 8 subjects per group. Within each group, 6 subjects will be randomized to receive ABBV-257 and 2 subjects will receive placebo. Subjects participating in one dose group will be ineligible to participate in another dose group in the study.
Detailed description
Multiple dose study designed to assess the safety, tolerability, pharmacokinetics, and immunogenicity of different dose levels of ABBV-257 given with methotrexate.
Interventions
BIOLOGICALABBV-257
subcutaneous injection
BIOLOGICALPlacebo
Placebo for ABBV-257
Sponsors
AbbVie
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of Rheumatoid Arthritis based on the 2010 American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) criteria, or ACR 1987 for patients with diagnosis prior 2011 ≥ 3 months. * Except for methotrexate (MTX), the subject must have discontinued all disease modifying anti-rheumatic drugs (DMARD) for at least 5 half-lives before the first dose of study drug, and undergone cholestyramine washout if received Leflunomide within the past 3 months. * Subject must have been on MTX therapy \> 3 months and on a stable dose (7.5 - 25 mg/week), for at least 4 weeks prior to the first dose of study drug. Subject must be able to continue on stable dose of MTX for the duration of study participation. * Body Mass Index (BMI) is 19 to 35, inclusive. (BMI is calculated as weight \[kg\] divided by height \[m2\].) * Judged to be in good general health as determined by the Investigator based upon the results of medical history, laboratory profile, physical examination and 12-lead electrocardiogram (ECG) performed at screening
Exclusion criteria
* Evidence of anti-ABBV-257 antibody results in a pre-study serum sample. * History of significant allergic reaction or significant sensitivity to any constituents of the study drug; or history of anaphylactic reaction to any agent (e.g., food products and bee sting); or history of a major reaction to any Immunoglobulin G (IgG) containing product. * History of persistent chronic or active infection(s) requiring hospitalization or treatment with intravenous or oral antimicrobials/antibiotics within 30 days prior to initial study drug administration. * History or evidence of active tuberculosis (TB) or the subject has evidence of risk factor for latent TB. * Clinically significant abnormal screening laboratory results as evaluated by the Investigator, including serum values of Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) greater than 2.25 × the upper limit of normal, or creatinine greater than 1.5 × the upper limit of normal, or absolute neutrophil count \< 1500 μ/L. * Subject has any medical condition or illness other than RA that is not well controlled with treatment that would, in the opinion of the investigator, preclude study participation or interfere with other symptoms of Rheumatoid Arthritis (RA).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to maximum observed serum concentration (Tmax) | Up to day 50 | This will be assessed using non-compartmental methods. |
| Proportion of subjects with adverse events | Up to day 193 | This will be collected through out the study |
| Change in Vital signs | From day 1 to day 193 | Vital signs including blood pressure and heart rate will be assessed |
| Change in Physical examination | From day 1 to day 193 | Changes in any physical exam assessed by the physician will be assessed. |
| Changes in Electrocardiogram (ECG) | From day 1 to day 193 | ECG measurements will be assessed |
| Maximum observed serum concentration (Cmax) | Up to day 50 | This will be assessed using non-compartmental methods. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity by measurement of Anti-drug antibody | Up to day 193 | Immunogenicity will be measured to see if the body has produced an immune response to ABBV-257 |
Other
| Measure | Time frame | Description |
|---|---|---|
| American College of Rheumatology (ACR) 50 response rate | Up to day 193 | ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant. |
| American College of Rheumatology (ACR) 70 response rate | Up to day 193 | ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant. |
| Change in Disease Activity Score 28 | From day 1 to day 193 | Calculated from tender joint, swollen joint and high sensitive C-reactive protein |
| American College of Rheumatology (ACR) 20 response rate | Up to day 193 | ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant. |
Countries
Germany
Outcome results
None listed